Efficacy and safety of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe psoriasis: 52-week results from OASIS-2, a multicenter, randomized, double-blind study

Authors
Category Primary study
JournalJournal of Clinical and Aesthetic Dermatology
Year 2021
This article has no abstract
Epistemonikos ID: a7e3b26dc70063291dee6b6ddf061fdae1dfdc3f
First added on: Feb 12, 2025